of Thank be update here good afternoon, on to is It truly you, Jeff, providing first our today, launch everyone. Oxbryta. and the exciting
how We launch are pleased with so the going is far. very
day that to Oxbryta's And the there is approved about FDA care it's trained team our priorities in on has about medicine. field sense was get I'm label. our One of and on engaging health physicians approval of educate professionals proud with and the the Oxbryta. out been label
Our cell the these the cell field care with XX% sickle sickle approximately treaters Most in disease, providers represent States. top team the nearly health the targeting together in country. health that is the are represent of care people that in X,XXX of United XX professionals States
care are on leave is plan while behind, located. where professionals, matter and built geographies, no we to strategy focused a one team they these coverage health designed educate Importantly, and our have to no
specialists therapeutic physicians. reached targets few half short XX% the have the decile highest X,XXX overall, nearly of a care approval, of approximately reached our States. professionals, in And United following just our have more than In months health
MSLs focusing cell on function has or key In medical team in Science addition, affairs leaders, are of approximately who disease. Liaisons Medical our XXX a sickle opinion
Oxbryta XX% have MSLs of about reached since approval. them Our
While to among Results Oxbryta, are awareness their specialists, of sickle physicians' showed early disease conducted XX%. a and than label. by has pulse from that reached and survey, eagerness initial the aided it Oxbryta about awareness we we of encouraged more learn after approved indication cell approval, top is
weeks, an a And just after this is result was for medicine impressive approved.
hematologists acts understanding action, of the Additionally, where an unique reporting paradigm cell upstream other directly of of given into its mechanism fits, Oxbryta agents. disease of sickle treatment are which
the survey of use our broad anemia intend increasing, beginning how commonly most also hemolysis. a cited differentiation, in consistent improving physicians reporting approved use potential include the We're to specialists reducing the Oxbryta, Oxbryta, to medicine benefits of hemoglobin with levels, and of label. In see
being we teams, report Even tried overall. larger who utilization the very of majority within physicians these often need the satisfied among care and And have some institutions, in medicine we before educate the with settings. broad specialists, the on to see with board, of Oxbryta, administrative Oxbryta
to sickle of leading time cell work we disease. terms educate lines, processes coverage, learn new specific up about And to drugs. approval, and formulary their payers considering In about for
with business we is our government first CMS following that we -- immediately their our launching product. allow launch, to is agreements immediately approval, our companies rebate for this first do This will requirement payers. Since a us filed
For to these has Medicaid, and each statement one agreements. a two quarters of activate generally time, load period to
meeting to We with share in payers their clinical are to reviews inform label approved and of the Oxbryta. engaged
As to provide report important to since mentioned, detailed we do not some are color those launch. payer But we discussions it's going. Jeff coverage are how metrics think, going on on,
pleased have -- it seen to report, from positive interest these we that is today, discussions in I'm that payers.
prescriptions we in had medical Medicaid, three payer and process. the Importantly, exceptions have during the Medicare, fourth meaning, segments, Commercial quarter, through all covered
November, abbreviated holidays. time have few an to a we added, and And Oxbryta Oxbryta when their late having was in that despite is the already the to frame proximity are payers formularies. approved This from
added state key with to Oxbryta On another label. coverage the one study Medicaid Alabama to is covered where the enrollment is been criteria. state HOPE broad Oxbryta consistent is formulary, where example, side, being the has with Florida
United of reimbursing of is claims terms insurers, Oxbryta. Healthcare In commercial
Blue covering of Blue And some with labeling. of Blue's Carolina Blue are and Cross Oxbryta, Shield as with coverage North Jersey policies Horizon of such now Cross broad Shield Blue the plans consistent New
SilverScript claims notably, Several Medicare of Humana largest the is insurer which and also Medicare plans Part reimbursing D Part are drugs. for D Oxbryta,
second payer each to we of cover achieving coverage, coverage we in Of overall, believe increasing to the track. decisions vary payer evaluations end are restrictions on payer for or plans quarters Oxbryta. to our expect to first course, the With with meetings and continue we choosing our be – we and third quarter with goal greater with focused the coverage year. the broad imposing expect Oxbryta of on beginning and by But not some imposing
of are With we respect launched patient as our hub proud Source, same-day to approval program the the FDA we that GBT on support high-touch the Oxbryta.
of Oxbryta While treatment that think approval. is earlier, sickle as it have These patients be to for when majority diseases started mentioned this gratifying patients of supported survey a deserves Source practice for and rare reported the finding Oxbryta. and It diseases. to is responsive within patients helpful pulse from unique were support and physicians best the successfully by GBT GBD specialists Source enrolled this and other their is important I and community cell access similar getting the community days we support
cell has the And need not However used providing this sickle will Continuous have everyone we're adopt historically understand proactively disease rare support is other in education key the more but support take which patient that to some we've in and before. finding process. are time. Especially been that under resourced. we and seen diseases we as programs
patients physicians critical Oxbryta about them and to reaching inform that launch. know will to we successful be Additionally the
of the we the review. of are materials FDA accelerated did approval. back for November Oxbryta's time this at As to to condition approval We a marketing required all Oxbryta's submit in
comments are marketing we've our working feedback to patient health on them, we the we for the currently waiting agency's pleased While marketing for on finalize care received professionals. are and that materials materials are still
our Our the of professional campaign to second this is goal half launch marketing care health year. in
be and are XX lifting of on ahead is We and that we metrics than career, based my us, start. realize more trends in happy having we're recognize need nimble drugs well to off our going emerging a to but to plans we but I according some we to ready have do the that great and heavy adjust launched launch flexible,
and turn I on priorities. our development provide to the activities our an and will over short-term now clinical update to Ted call long-term
